|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
Mini Oral Session: GU Tumors, Prostate
|
|
| Quality of Life and Patient-relevant Endpoints With Darolutamide in the Phase 3 ARASENS Study
|
| Karim Fizazi, MD, Ph.D.
|
| The 2022 European Society of Medical Oncology annual meeting featured a prostate cancer session, including a presentation by Dr. Karim Fizazi discussing quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study. Early treatment intensification with darolutamide + ADT + docetaxel improved patient-relevant endpoints, with reduced all-cause and prostate cancer related deaths and similar incidences and time course for most adverse events of special interest vs placebo + ADT + docetaxel, notably with no increase in cardiac disorders.
|
|
|
|
|
|
| Duration of Androgen Suppression with Post-Operative Radiotherapy (DADSPORT): A Collaborative Meta-Analysis of Aggregate Data |
| Sarah Burdett |
| Sarah Burdett discussing DADSPORT, a collaborative meta-analysis of aggregate data to assess duration of androgen suppression with post-operative radiotherapy. The DADSPORT meta-analysis collaboration conducted a systematic review and meta-analysis of results from NRG/RTOG 9601, GETUG-AFU 16, NRG/RTOG 0534, and the newly-available, RADICALS-HD trials to assess the effect of hormone therapy in men receiving radiotherapy following radical prostatectomy for localized prostate cancer. |
|
|
|
|
|
| Quantity versus Quality of Life OR Quantity and Quality of Life Discussion |
| Nicolas Mottet, MD, Ph.D.
|
| Nicolas Mottet discussed two key abstracts including “Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data” presented by Dr. Sarah Burdett and “Quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study” presented by Dr. Karim Fizazi.
|
|
|
|
|
|
|
|
|
|
|
| Differential Treatment Response with Nodal Metastases in mHSPC and Evaluation of Nodal Burden as a Prognostic Biomarker -Ancillary Studies of the Docetaxel and Abiraterone Acetate and Prednisolone Phase III Trials from STAMPEDE |
| Áine Haran, BSc (Hons), BMBS, MRCS |
| Áine Haran discussed ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE, specifically differential treatment response with nodal metastases in mHSPC and evaluation of nodal burden as a prognostic biomarker. |
|
|
|
|
|
| 8-Month PSA Strongly Predicts Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial |
| Gwenaelle Gravis Mescam, MD |
| Gwenaelle Mescam discussed the 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC) in the PEACE-1 phase 3 trial. 8-month PSA value strongly predicts both rPFS and OS in men with mCSPC in PEACE-1. There was a significantly higher number of patients that had a PSA <= 0.20 ng/mL with the combination of ADT + docetaxel + abiraterone acetate + prednisone arms versus ADT + docetaxel. |
|
|
|
|
|
| Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion |
| Boris Hadaschik, MD
|
| Boris Hadaschik discussing two abstracts including “Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal burden as a prognostic biomarker -ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE” presented by Dr. Áine Haran and “8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase 3 trial” presented by Dr. Gwenaelle Gravis Mescam.
|
|
|
|
|
|
| Pembrolizumab + Olaparib Versus Abiraterone or Enzalutamide for Patients with Previously Treated mCRPC: Randomized Open-Label Phase 3 KEYLYNK-010 Study |
| Evan Yu, MD |
| Evan Yu discussing the results of KEYLYNK-010, a randomized, open-label phase 3 study assessing pembrolizumab + olaparib versus abiraterone or enzalutamide for patients with previously treated mCRPC. Indeed, there is an unmet need for effective therapies for patients with heavily pretreated mCRPC. KEYLYNK-010 evaluated the efficacy and safety of pembrolizumab + olaparib vs abiraterone or enzalutamide for molecularly unselected patients with mCRPC after a next-generation hormonal agent and docetaxel. |
|
|
|
|
|
|
|
|
|
|
| Cabazitaxel Every 2 Weeks Versus Every 3 Weeks in Older Patients with mCRPC: The CABASTY Randomized Phase III Trial |
| Stephane Oudard, MD, Ph.D.
|
| Stephane Oudard discussed the results of CABASTY, a randomized, phase III trial assessing cabazitaxel every 2 weeks versus every 3 weeks in older patients with mCRPC. The CABASTY trial met its primary endpoint – in this heavily pretreated elderly mCRPC population (50% >= 75 years), cabazitaxel 16 mg/m2 q2w plus G-CSF significantly reduced the rate of grade >= 3 neutropenia and/or neutropenic complications versus cabazitaxel 25 mg/m2 q3w plus G-CSF. |
|
|
|
|
|
| Preliminary Phase 2 Results of the CYPIDES Study of ODM-208 in mCRPC Cancer Patients
|
| Karim Fizazi, MD, Ph.D.
|
| Karim Fizazi discussed the preliminary results of CYPIDES, a phase 2 trial of ODM-208 in mCRPC cancer patients. ODM-208 is a first in class, oral, non-steroidal, and selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis.
|
|
|
|
|
|
| Development of Novel Treatments in Metastatic Prostate Cancer Discussion |
| Martijn P. Lolkema, MD
|
| Martijn Lolkema discussed four abstracts presented at ESMO 2022 including SAKK 08/14 - IMPROVE Investigation of metformin in patients with mCRPC in combination with enza vs enza alone, the KEYLYNK-010 study pembro + olaparib vs abi or enza for pts with previously treated mCRPC, the CABASTY trial Cabazitaxel every 2 weeks vs every 3 weeks in older patients with mCRPC, and the CYPIDES study of ODM-208 in mCRPC cancer patients.
|
|
|
|
|
|
|
